Biogen Inc (BIIB)

NASDAQ
Currency in USD
118.84
-0.67(-0.56%)
Closed·
After Hours
119.72+0.89(+0.75%)
·
BIIB Scorecard
Full Analysis
13 analysts have revised their earnings downwards for the upcoming period
Earnings results expected in 4 days
Fair Value
Day's Range
117.14119.62
52 wk Range
110.04238.00
Key Statistics
Edit
Prev. Close
119.51
Open
119.13
Day's Range
117.14-119.62
52 wk Range
110.04-238
Volume
1.54M
Average Volume (3m)
1.73M
1-Year Change
-43.11%
Book Value / Share
114.71
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BIIB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
190.50
Upside
+60.30%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth
Show more

Biogen Inc Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Employees
7605

Biogen Inc SWOT Analysis


Neuroscience Pionee
Biogen leads in neurodegenerative diseases, facing challenges and opportunities in Alzheimer's and rare neurological conditions
Pipeline Potential
Explore Biogen's diverse pipeline, including Leqembi for Alzheimer's and Skyclarys for Friedreich's ataxia, with projected peak sales of $1.7 billion
Financial Health
Delve into Biogen's strong financials, with a P/E ratio of 12.28x and free cash flow yield of 14%, suggesting potential undervaluation
Strategic Outlook
Analyst price targets range from $156 to $292, reflecting varied views on Biogen's growth prospects and strategic initiatives
Read full SWOT analysis

Biogen Inc Earnings Call Summary for Q3/2024

  • Q3 revenue down 3% to $2.5B; non-GAAP EPS at $4.08. Full-year EPS guidance raised to $16.10-$16.60, reflecting 11% YoY growth.
  • LEQEMBI revenue up 66% QoQ; ZURZUVAE up 49%. Rare disease franchise grew 10%, driven by SKYCLARYS launch.
  • Pipeline potential peak sales estimated at $14B. Focus on neurology, immunology, and rare diseases for sustainable growth.
  • CFO Mike McDonnell to retire; Robin Kramer appointed as successor. Higher SG&A spending expected in Q4 for new product launches.
  • Highest free cash flow since Q2 2021 at $901M. Company positioned for acquisitions and investment in strategic priorities.
Last Updated: 2024-10-30, 06:46 p/m
Read Full Transcript

Compare BIIB to Peers and Sector

Metrics to compare
BIIB
Peers
Sector
Relationship
P/E Ratio
10.7x−2.5x−0.5x
PEG Ratio
0.26−0.090.00
Price/Book
1.0x2.1x2.6x
Price / LTM Sales
1.8x14.4x2.9x
Upside (Analyst Target)
55.7%113.0%60.5%
Fair Value Upside
Unlock14.8%8.5%Unlock

Analyst Ratings

16 Buy
19 Hold
0 Sell
Ratings:
35 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 190.50
(+60.30% Upside)

Earnings

Latest Release
Feb 12, 2025
EPS / Forecast
3.44 / 3.41
Revenue / Forecast
2.45B / 2.41B
EPS Revisions
Last 90 days

People Also Watch

493.84
VRTX
+0.28%
77.91
ANET
+3.48%
109.19
DECK
-1.32%
39.63
ON
-0.83%
113.34
ARM
+1.19%

FAQ

What Is the Biogen (BIIB) Stock Price Today?

The Biogen stock price today is 118.84

What Stock Exchange Does Biogen Trade On?

Biogen is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Biogen?

The stock symbol for Biogen is "BIIB."

What Is the Biogen Market Cap?

As of today, Biogen market cap is 17.40B.

What is Biogen Earnings Per Share?

The Biogen EPS is 11.21.

What Is the Next Biogen Earnings Date?

Biogen will release its next earnings report on May 01, 2025.

From a Technical Analysis Perspective, Is BIIB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.